Drug Profile
XMT 1107
Alternative Names: XMT-1107; XMT-1191Latest Information Update: 18 May 2018
Price :
$50
*
At a glance
- Originator Mersana Therapeutics
- Class Antineoplastics; Drug conjugates; Polymers
- Mechanism of Action Methionine aminopeptidase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 14 May 2018 Mersana Therapeutics has patent protection in USA and foreign countries across its platforms and programmes
- 14 May 2018 Mersana Therapeutics has patent protection for its Fleximer polymer-based Dolaflexin platform in USA
- 09 Mar 2017 Mersana Therapeutics has patent protection for Fleximer-ADC platform technology in the European Union